Marksans Pharma Limited Stock Bombay S.E.

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:53 2024-07-12 am EDT 5-day change 1st Jan Change
189 INR -1.72% Intraday chart for Marksans Pharma Limited +0.59% +17.50%
Sales 2024 21.77B 261M Sales 2025 * 26.7B 320M Capitalization 85.72B 1.03B
Net income 2024 3.14B 37.56M Net income 2025 * 3.97B 47.48M EV / Sales 2024 3.16 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.21 x
P/E ratio 2024
22 x
P/E ratio 2025 *
21.5 x
Employees 852
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.72%
1 week+0.59%
Current month+18.98%
1 month+18.98%
3 months+15.99%
6 months+15.88%
Current year+17.50%
More quotes
1 week
184.00
Extreme 184
197.15
1 month
157.35
Extreme 157.35
197.15
Current year
126.05
Extreme 126.05
197.15
1 year
93.85
Extreme 93.85
197.15
3 years
38.70
Extreme 38.7
197.15
5 years
9.90
Extreme 9.9
197.15
10 years
9.90
Extreme 9.9
197.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 92-04-15
Director of Finance/CFO 55 02-09-05
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 49 21-08-10
Chief Executive Officer 52 92-04-15
Director/Board Member 52 14-09-24
More insiders
Date Price Change Volume
24-07-12 189 -1.72% 69,444
24-07-11 192.3 +2.29% 242,188
24-07-10 188 +0.62% 288,065
24-07-09 186.8 -1.03% 88,695
24-07-08 188.8 +0.48% 305,673

Delayed Quote Bombay S.E., July 12, 2024 at 06:00 am EDT

More quotes
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
189.2 INR
Average target price
215 INR
Spread / Average Target
+13.66%
Consensus

Annual profits - Rate of surprise